Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor
Early Phase 1
Completed
- Conditions
- Neuroendocrine Tumor
- Interventions
- Drug: 90Y-DOTA-TOCDrug: 68Ga-DOTA-TOC
- First Posted Date
- 2017-06-23
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- Thomas Hope
- Target Recruit Count
- 10
- Registration Number
- NCT03197012
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Evaluation of Gallium-68-HBED-CC-PSMA Imaging in Prostate Cancer Patients
Phase 2
Completed
- Conditions
- Prostate Cancer
- Interventions
- Drug: Ga-68 labeled HBED-CC PSMADevice: Positron Emission Tomography (PET) image combined with Computed Tomography (CT) (PET/CT)Device: Positron Emission Tomography (PET) image combined with Magnetic Resonance Imaging (MRI) (PET/MRI)
- First Posted Date
- 2015-11-23
- Last Posted Date
- 2020-12-22
- Lead Sponsor
- Thomas Hope
- Target Recruit Count
- 225
- Registration Number
- NCT02611882
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
© Copyright 2025. All Rights Reserved by MedPath